Close Menu

NEW YORK ─ Luminex on Tuesday announced preliminary fourth quarter revenue growth of approximately 23 percent year over year.

For the quarter ended Dec. 31, 2020, the Austin, Texas-based diagnostics company expects to report revenues of approximately $111 million, compared to $90.5 million in Q4 2019, which would beat analysts' average estimate for revenues of $104.6 million.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The FDA and CDC call for a pause in administering Johnson & Johnson's SARS-CoV-2 vaccine while reports of rare blood clots are looked into, reports the Wall Street Journal.

According to the Associated Press, a Swiss program aims to shepherd long-term science projects and diplomacy.

CNN reports that two new studies suggest the B.1.1.7 SARS-CoV-2 variant may be more transmissible, but may not lead to more severe disease.

In PNAS this week: analysis of pathway affecting acute kidney injury, parental-specific allelic expression in horse placenta, and more.